Birth control pills are used by over 150 million women worldwide. They are incredibly effective at preventing pregnancy.
But the most common type has long contained a specific, strong synthetic estrogen called ethinyl estradiol (EE). While effective, EE is linked to a small but increased risk of venous thromboembolism (VTE)—a type of blood clot.
For a healthy young woman, this absolute risk remains low. But it is a real concern, especially for those with other risk factors like smoking or a family history of clots. It has been a fixed point in the risk-benefit discussion for over 50 years.
The Surprising Shift
The old thinking was simple: the pill’s clot risk was largely an unavoidable trade-off. Different pills had different risk levels, but the estrogen component was a key player.
Here’s the twist.
The new review highlights that it’s not just which pill, but what kind of estrogen it uses that may matter most. Researchers are now looking closely at pills that replace the synthetic EE with forms of “natural” estrogen.
These are body-identical molecules like estradiol (E2) or estetrol (E4). They are not derived from plants like “natural” supplements. Instead, they are chemically identical to the estrogen a woman’s own body makes.
How the New Pills Work Differently
Think of your body’s blood-clotting system as a careful balancing act. On one side are factors that help clots form to stop bleeding. On the other are factors that prevent unwanted clots.
The synthetic estrogen EE strongly tips this balance toward clotting. It acts like a persistent signal, amplifying the liver’s production of clotting proteins.
The natural estrogens in these newer pills deliver a gentler, more balanced signal. They still provide the necessary estrogenic effect to control the menstrual cycle and prevent pregnancy. But they appear to cause less disruption to the liver and the clotting system.
The result is a more stable equilibrium.
A Deep Look at the Evidence
The review, published in Frontiers in Medicine, analyzed decades of data. It looked at real-world health records, clinical trial results, and laboratory studies on blood clotting.
It compared the classic EE-based pills to the newer natural estrogen options. The goal was to see beyond the marketing and find the true biological differences.
The most patient-relevant finding is clear. Pills containing natural estrogens (like E2 or E4) are consistently linked to a lower risk of blood clots than pills containing EE.
For example, large meta-analyses—studies that combine data from many other studies—show that pills with estradiol valerate (E2V) carry a lower VTE risk than even the safest EE-based pills.
The data isn’t just from watching who gets clots. Laboratory tests on women taking these pills confirm it. Their “global hemostasis” profiles—a overall snapshot of their clotting balance—show less disturbance.
But here’s the crucial detail.
This doesn’t mean these newer pills are risk-free. All hormonal contraception carries some level of clot risk. The finding is about relative safety. For women who choose a combined oral contraceptive, the evidence now suggests natural estrogen pills may be the safer choice within that category.
The review authors conclude that the safest combined pills in terms of thrombotic risk are likely those containing a natural estrogen paired with a modern, non-androgenic progestin (the other hormone in the pill). This challenges the long-held view and gives doctors a clearer, evidence-based option to recommend.
If you are concerned about blood clot risk on birth control, this information is powerful. It gives you a specific topic to discuss with your gynecologist or healthcare provider.
The important thing to know is that these pills are not experimental. They are already approved and on the market in many countries, including the U.S. and across Europe. Brands like Natazia (E2V/dienogest) and Nextstellis (E4/drospirenone) fall into this category.
You can ask your doctor: “Is a pill with a natural estrogen like estradiol or estetrol a good option for me?”
Understanding the Limits
This review synthesizes existing evidence; it is not a new clinical trial. While the data is strong, more long-term, real-world use data is always valuable. Also, “natural estrogen” pills may not be the best fit for every woman. Individual health history is the most important factor in any prescription.
The conversation around birth control is evolving from just effectiveness to a more nuanced view of safety and tolerability. This research helps guide that shift. It provides a solid scientific foundation for why these newer pills are different.
As more women and doctors become aware of this distinction, it could lead to a change in prescribing patterns. The goal is smarter, safer, and more personalized choices for every woman seeking contraception.
The future of birth control isn’t just about new drugs—it’s about using deeper science to make better use of the options we already have.
